Published in Haemophilia on December 16, 2011
Capturing daily assessments and home treatment of congenital hemophilia with inhibitors: design, disposition, and implications of the Dosing Observational Study in Hemophilia (DOSE). J Blood Med (2012) 0.81
Beyond stopping the bleed: short-term episodic prophylaxis with recombinant activated factor FVII in haemophilia patients with inhibitors. Blood Transfus (2015) 0.75
Mixing and administration times of bypassing agents: observations from the Dosing Observational Study in Hemophilia (DOSE). J Blood Med (2014) 0.75
Evaluation of Aryoseven Safety (Recombinant Activated Factor VII) in Patients with Bleeding Disorders (An Observational Post-Marketing Surveillance Study). Iran J Pathol (2016) 0.75
Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. Mol Ther (2000) 3.32
NDR1, a pathogen-induced component required for Arabidopsis disease resistance. Science (1997) 3.16
Lysosome biogenesis requires Rab9 function and receptor recycling from endosomes to the trans-Golgi network. J Cell Biol (1994) 2.95
Membrane targeting of the small GTPase Rab9 is accompanied by nucleotide exchange. Nature (1994) 2.50
Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. J Clin Oncol (1996) 2.44
The evolution of alpha-fetoprotein and albumin. I. A comparison of the primary amino acid sequences of mammalian alpha-fetoprotein and albumin. J Biol Chem (1981) 1.77
A national syndromic surveillance system for England and Wales using calls to a telephone helpline. Euro Surveill (2006) 1.66
Sustained and complete phenotype correction of hemophilia B mice following intramuscular injection of AAV1 serotype vectors. Mol Ther (2001) 1.65
Release and metabolism of arachidonic acid in human neutrophils. J Biol Chem (1981) 1.62
Brief report: complete deficiency of plasminogen-activator inhibitor type 1 due to a frame-shift mutation. N Engl J Med (1992) 1.57
Molecular cloning of CD44R1 and CD44R2, two novel isoforms of the human CD44 lymphocyte "homing" receptor expressed by hemopoietic cells. J Exp Med (1991) 1.55
Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia. Gene Ther (1998) 1.52
Bazex syndrome (acrokeratosis paraneoplastica). An analytic review. Medicine (Baltimore) (1991) 1.49
Prevalence and risk factors of cardiovascular disease (CVD) events among patients with haemophilia: experience of a single haemophilia treatment centre in the United States (US). Haemophilia (2011) 1.47
Impact of non-CTCL dermatologic diagnoses and adjuvant therapies on cutaneous T-cell lymphoma patients treated with total skin electron beam radiation therapy. Int J Radiat Oncol Biol Phys (1994) 1.44
High-dose BEAM chemotherapy with autologous peripheral blood progenitor-cell transplantation for unselected patients with primary refractory or relapsed Hodgkin's disease. Ann Oncol (2000) 1.43
Fanconi anemia and novel strategies for therapy. Blood (1994) 1.39
Platelet activating factor. Stimulation of the lipoxygenase pathway in polymorphonuclear leukocytes by 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine. J Biol Chem (1982) 1.39
Home treatment of mild to moderate bleeding episodes using recombinant factor VIIa (Novoseven) in haemophiliacs with inhibitors. Thromb Haemost (1998) 1.35
Human plasminogen activator inhibitor-1 (PAI-1) deficiency: characterization of a large kindred with a null mutation in the PAI-1 gene. Blood (1997) 1.34
Rab-GDI presents functional Rab9 to the intracellular transport machinery and contributes selectivity to Rab9 membrane recruitment. J Biol Chem (1994) 1.33
Engraftment of hematopoietic progenitor cells transduced with the Fanconi anemia group C gene (FANCC). Hum Gene Ther (1999) 1.28
The molecular defect in type IIB von Willebrand disease. Identification of four potential missense mutations within the putative GpIb binding domain. J Clin Invest (1991) 1.26
Plasminogen deficiency. Haemophilia (2008) 1.22
Clinical evaluation of an advanced category antihaemophilic factor prepared using a plasma/albumin-free method: pharmacokinetics, efficacy, and safety in previously treated patients with haemophilia A. Haemophilia (2004) 1.19
Sustained expression of human factor VIII in mice using a parvovirus-based vector. Blood (2000) 1.19
Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry. Haemophilia (2005) 1.18
Alternative splicing of CD44 pre-mRNA in human colorectal tumors. Biochem Biophys Res Commun (1994) 1.18
Consensus recommendations for use of central venous access devices in haemophilia. Haemophilia (2004) 1.14
Clinical pharmacology and safety evaluation of Timentin. Am J Med (1985) 1.12
Plasma and albumin-free recombinant factor VIII: pharmacokinetics, efficacy and safety in previously treated pediatric patients. J Thromb Haemost (2008) 1.11
Development of the superoxide-generating system during differentiation of the HL-60 human promyelocytic leukemia cell line. J Biol Chem (1984) 1.11
Cisplatin, fluorouracil, and leucovorin induction chemotherapy followed by concurrent cisplatin chemoradiotherapy for organ preservation and cure in patients with advanced head and neck cancer: long-term follow-up. J Clin Oncol (2004) 1.10
Second solid tumors in patients with Hodgkin's disease cured after radiation or chemotherapy plus adjuvant low-dose radiation. J Clin Oncol (1996) 1.07
Comparison of clot-based, chromogenic and fluorescence assays for measurement of factor VIII inhibitors in the US Hemophilia Inhibitor Research Study. J Thromb Haemost (2013) 1.05
Ligand binding specificity of alternatively spliced CD44 isoforms. Recognition and binding of hyaluronan by CD44R1. J Biol Chem (1994) 1.05
Human alpha spectrin II and the Fanconi anemia proteins FANCA and FANCC interact to form a nuclear complex. J Biol Chem (1999) 1.03
Degradation rates of acetylcholine receptors can be modified in the postjunctional plasma membrane of the vertebrate neuromuscular junction. J Cell Biol (1986) 1.03
Plasminogen activator inhibitor type 1 deficiency. Haemophilia (2008) 1.02
Platelet activation releases megakaryocyte-synthesized apolipoprotein J, a highly abundant protein in atheromatous lesions. Am J Pathol (1993) 1.01
The Copper T 220C: a new long-acting copper intrauterine contraceptive device. Am J Obstet Gynecol (1976) 0.99
VERITAS-PRN: a new measure of adherence to episodic treatment regimens in haemophilia. Haemophilia (2009) 0.96
Pharmacokinetics of recombinant factor IX in relation to age of the patient: implications for dosing in prophylaxis. Haemophilia (2001) 0.96
Differential effects of infliximab on absolute circulating blood leucocyte counts of innate immune cells in early and late rheumatoid arthritis patients. Clin Exp Immunol (2012) 0.95
F8 haplotype and inhibitor risk: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort. Haemophilia (2012) 0.94
Adhesive interactions between alternatively spliced CD44 isoforms. J Biol Chem (1995) 0.94
Temocillin concentrations in human tissues. Drugs (1985) 0.93
Vitamin K deficiency in the newborn infant: prevalence and perinatal risk factors. J Pediatr (1986) 0.93
The variant mRNA isoform of human metastasis gene (CD44V) detected in the cell lines of human hepatocellular carcinoma. Biochem Mol Biol Int (1994) 0.93
Platelets inhibit fibrinolysis in vitro by both plasminogen activator inhibitor-1-dependent and -independent mechanisms. Blood (1994) 0.92
CD44V6 expression in human colorectal carcinoma. Hum Pathol (1998) 0.92
Effect of phagocytosis and ionophores on release and metabolism of arachidonic acid from human neutrophils. Lipids (1981) 0.92
Phenotypic correction of Fanconi anemia group C knockout mice. Blood (2000) 0.92
Retroviral mediated gene transfer of the Fanconi anemia complementation group C gene to hematopoietic progenitors of group C patients. Hum Gene Ther (1997) 0.92
The relationship of mutations in the MTHFR, prothrombin, and PAI-1 genes to plasma levels of homocysteine, prothrombin, and PAI-1 in children and adults. Thromb Haemost (1999) 0.91
RNA synthesis in myeloma cells synchronized by isoleucine starvation. Nucleic Acids Res (1978) 0.91
Mechanism of arachidonic acid release in human polymorphonuclear leukocytes. Biochim Biophys Acta (1983) 0.90
Induction of tolerance to human factor VIII in mice. Blood (2001) 0.90
Delayed somatic growth and pubertal development in human immunodeficiency virus-infected hemophiliac boys: Hemophilia Growth and Development Study. J Pediatr (1994) 0.89
Use of rituximab and irradiated donor-derived lymphocytes to control Epstein-Barr virus-associated lymphoproliferation in patients undergoing related haplo-identical stem cell transplantation. Bone Marrow Transplant (1999) 0.89
Comparison of the calcium ionophore and phorbol myristate acetate on the initiation of the respiratory burst in human neutrophils. Infect Immun (1982) 0.87
Variability in platelet- and collagen-binding defects in type 2M von Willebrand disease. Haemophilia (2013) 0.87
Antithrombin-III for the treatment of chemotherapy-induced organ dysfunction following bone marrow transplantation. Bone Marrow Transplant (1997) 0.86
Functional correction of fanconi anemia group C hematopoietic cells by the use of a novel lentiviral vector. Mol Ther (2001) 0.86
Use of recombinant activated factor VII in patients with Glanzmann's thrombasthenia: a review of the literature. Haemophilia (2014) 0.86
Thyroid lymphoma. The case for combined modality therapy. Cancer (1994) 0.86
Fanconi anemia C protein acts at a switch between apoptosis and necrosis in mitomycin C-induced cell death. Exp Cell Res (1999) 0.85
Dermatomyositis and lichen myxedematosus. A clinical, histopathological and electron microscopic study. Dermatologica (1973) 0.85
Major differences in bleeding symptoms between factor VII deficiency and hemophilia B. J Thromb Haemost (2009) 0.85
Gonorrhea screening program in a women's hospital outpatient department: results and analysis of risk factors. J Am Vener Dis Assoc (1976) 0.85
Endogenous canine FIX antigen exists in Chapel Hill strain hemophilia B canine. Thromb Haemost (1999) 0.85
Single-dose pharmacokinetics of intravenous clavulanic acid with amoxicillin in pediatric patients. Antimicrob Agents Chemother (1983) 0.84
Haemophilia Experiences, Results and Opportunities (HERO) Study: survey methodology and population demographics. Haemophilia (2013) 0.84
Surgical experience with rFVIIa (NovoSeven) in congenital haemophilia A and B patients with inhibitors to factors VIII or IX. Haemophilia (2011) 0.84
A phase II study of outpatient chemotherapy with cisplatin, 5-fluorouracil, and leucovorin in nasopharyngeal carcinoma. Cancer (1994) 0.84
Haemophilia Experiences, Results and Opportunities (HERO) Study: influence of haemophilia on interpersonal relationships as reported by adults with haemophilia and parents of children with haemophilia. Haemophilia (2014) 0.84
Comparative analysis of three nucleic acid-based detection systems for hepatitis C virus RNA in plasma from liver transplant recipients. Mol Cell Probes (1996) 0.84
Pharmacokinetics of von Willebrand factor and factor VIIIC in patients with severe von Willebrand disease (type 3 VWD): estimation of the rate of factor VIIIC synthesis. Cooperative Study Groups. Br J Haematol (1996) 0.84
Reconstitution of Rab9 endosomal targeting and nucleotide exchange using purified Rab9-GDP dissociation inhibitor complexes and endosome-enriched membranes. Methods Enzymol (1995) 0.84
New high-technology products for the treatment of haemophilia. Haemophilia (2004) 0.83
Variability of in vivo recovery of factor IX after infusion of monoclonal antibody purified factor IX concentrates in patients with hemophilia B. The Mononine Study Group. Thromb Haemost (1995) 0.82
Distinct domains of alphaIIbbeta3 support different aspects of outside-in signal transduction and platelet activation induced by LSARLAF, an alphaIIbbeta3 interacting peptide. Thromb Haemost (2001) 0.82
A phase I study of paclitaxel for mobilization of peripheral blood progenitor cells. Bone Marrow Transplant (1999) 0.82
Toxic erythema of chemotherapy following i.v. BU plus fludarabine for allogeneic PBSC transplant. Bone Marrow Transplant (2012) 0.82
Pharmacokinetics of ticarcillin and clavulanic acid (timentin) in relation to renal function. Antimicrob Agents Chemother (1986) 0.81
Screening recombinant DNA libraries: a rapid and efficient method for isolating cDNA clones utilizing the PCR. Biotechniques (1991) 0.81
Postpartum intracranial venous thrombosis associated with dysfunctional protein C and deficiency of protein S. Obstet Gynecol (1990) 0.81
The multispecific cell adhesion molecule CD44 is represented in reticulocyte cDNA. Biochem Biophys Res Commun (1991) 0.81
Experience with a third generation recombinant factor VIII concentrate (Advate) for immune tolerance induction in patients with haemophilia A. Haemophilia (2009) 0.81
A deficiency in a 230 kDa DNA repair protein in fanconi anemia complementation group A cells is corrected by the FANCA cDNA. Carcinogenesis (1999) 0.80
Patient- and caregiver-reported bleeding symptoms and reasons for starting and stopping treatment with recombinant factor VIIa: analysis of the Dosing Observational Study in Haemophilia (DOSE). Haemophilia (2012) 0.80
Neutropenic infections in 100 patients with non-Hodgkin's lymphoma or Hodgkin's disease treated with high-dose BEAM chemotherapy and peripheral blood progenitor cell transplant: out-patient treatment is a viable option. Bone Marrow Transplant (1999) 0.80
Pulmonary metastases in neuroblastoma. AJR Am J Roentgenol (1982) 0.80
Can scoring influence athletic performance? Sex and the athlete. J Am Coll Health Assoc (1975) 0.80